Compare Hyatt Hotels Corporation (H) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Johnson & Johnson — how do they compare? Hyatt Hotels Corporation trades at $161.5 (market cap $15.02B), while Johnson & Johnson trades at $261.08 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 41.2× Hyatt Hotels Corporation's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and Johnson & Johnson for 129 Days on average.
| H | JNJ | |
|---|---|---|
Market Cap | $15.02B | $618.09B |
Volume | 842,340 | 6,050,983 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $278.43 |
52-Week Low | $135.42 | $186.00 |
Typical Hold Time | 148 Days | 129 Days |
Enterprise Value | $18.93B | $646.37B |
Dividend Yield | 0.38% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $160.27, up 1.99% with recent earnings beats but faces bearish technical signals. The stock shows mixed fundamentals with a high P/E of 196.83 and modest net income margin of 1.1%, though revenue growth to $7.10B in 2025 and strategic collaborations with Delta Air Lines highlight expansion efforts. Analyst consensus is moderately bullish with a $197.77 price target, but negative cash flow trends and elevated debt levels present challenges.
Outlook remains cautious due to valuation concerns and operational headwinds, though long-term growth initiatives offer potential upside. Key risks include profit margin volatility, high leverage, and competitive pressure. Investors should weigh analyst optimism against fundamental weaknesses before positioning.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
